Quantcast

Industry news that matters to you.  Learn more

PROOF Centre Collaboration Focuses on Prognostic Biomarkers for Chronic Kidney Disease

Reading time: 2 – 4 minutes

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) recently announced a new partnership with AstraZeneca and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) to develop a blood test to predict the rate of disease progression in patients with chronic kidney disease (CKD).

For the discovery phase of the project, PROOF Centre and AstraZeneca researchers will leverage the large cohort and rich clinical data available from the CanPREDDICT study. The collective team of clinical, computational, technical and biological experts will use the PROOF Centre’s computationally-driven omics biomarker development pipeline to identify genomic and proteomic biomarkers that can discriminate patients who have rapid versus slow CKD progression. The PROOF Centre will support the analysis process from front-end experimental design to downstream statistical and biological analysis.

“Biomarkers to better predict disease progression will be a valuable tool to provide more personalized care for patients suffering from CKD. If developed as a blood test that corresponds to different patient trajectories, it will offer clinicians a better way of knowing which patients need more intensive medical attention and management,” says CanPREDDICT lead investigator and Head of UBC Division of Nephrology, Dr. Adeera Levin.

Thus, a prognostic test will enable clinicians to more aggressively manage CKD in patients expected to rapidly decline, potentially delaying end-stage renal disease. Patients whose kidney function is predicted to stay stable or improve can be monitored less frequently, saving health care dollars.

Such a test won’t only benefit patient care, it will also be extremely valuable for the research and drug development community.

“Chronic kidney disease is a strategically important research area for AstraZeneca. Knowing which patients with this disease are likely to face rapid decline and which ones are not, is a major hurdle in clinical trials for new therapeutics,” Dr. Peter Greasley, Director Clinical Research at AstraZeneca explains. “More than 80% of AstraZeneca’s portfolio across small and large molecules has a personalised healthcare approach and biomarkers identified in this collaboration will enable patient stratification that in turn may reduce the time, number of patients, and costs needed for such trials.”

“We are pleased to partner with AstraZeneca and CanPREDDICT in an exciting effort to develop new biomarker tools that will have a major impact in drug development and patient care,” says Dr. Bruce McManus, CEO of the PROOF Centre.

“This collaboration will lay the groundwork for improving clinical care for CKD patients by expediting the drug-development process, reducing disease-related uncertainty for patients and their physicians, and allowing for trajectory-specific management strategies—ultimately reducing health care costs and improving patients’ quality of life,” says McManus.

“Today’s announcement builds on our deep commitment to both improving care and supporting leading-edge Canadian health sciences leadership in cardiovascular and metabolic diseases,” said Neil Maresky, VP of Scientific Affairs, AstraZeneca Canada. “We are proud to support work that promises to create meaningful advances in the treatment of chronic kidney disease for patients around the world, and excited that this research is being led right here in Canada.”

Source: CNW